Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Emerging Therapies for Hair Loss in 2026: Prolactin Receptor Inhibitors, PP405, and Androgen Receptor Degraders
Description
The speaker reviews three emerging hair-loss therapies and emphasizes separating hype from evidence. First, prolactin receptor inhibitors (HMI-115 and ABS-201) are based on evidence that prolactin can drive hair follicles into catagen and reduce pigmentation; preclinical studies and early phase safety data are promising, but human efficacy is still unproven. Second, PP405 targets mitochondrial pyruvate metabolism to shift stem-cell energy use and may reactivate follicles; early phase 2 press-release data suggest increased hair density in some patients with good safety and no systemic absorption, but results are not yet peer-reviewed. Third, GT20029 is an androgen receptor degrader using PROTAC technology to eliminate the receptor rather than merely block it; it appears to be the most advanced candidate, with published phase 2 data showing improved hair counts, minimal systemic exposure, and good safety, and it has moved into phase 3. Overall, the talk highlights a rapidly evolving pipeline with novel mechanisms that may eventually expand treatment options for androgenetic alopecia, while noting that stronger human data are still needed for several of these agents.
View moreConclusions
- Prolactin receptor inhibition is biologically plausible for hair loss, but human efficacy data are still limited and not yet definitive.
- ABS-201 and HMI-115 show encouraging preclinical safety and early activity, but their clinical benefit in humans remains unproven.
- PP405 has a novel mechanism that may reactivate hair follicle stem cells by shifting metabolism toward glycolysis, and early trial signals are promising but still preliminary.
- The early PP405 data suggest topical treatment may be safe, have minimal systemic absorption, and produce relatively rapid hair-density improvements, but peer-reviewed confirmation is needed.
- GT20029 appears to be the most advanced of the new agents discussed and has shown encouraging phase 2 results with acceptable safety and low systemic exposure.
- Androgen receptor degradation represents a strong mechanistic strategy for androgenetic alopecia because it removes the receptor rather than merely reducing androgen levels.
- Overall, the field is moving toward mechanism-based, precision-targeted therapies that may complement existing hair-loss treatments rather than replace them immediately.
- Despite substantial excitement and media hype, most of these emerging therapies still require stronger published human data before they can be considered established treatments.
- https://www.sciencedirect.com/topics/medicine-and-dentistry/prolactin-synthesis